Definition
Treatment-resistant depression (TRD) is generally defined as major depressive disorder that has failed to respond adequately to at least two different antidepressant medications, each given at an adequate dose for an adequate duration (typically six to eight weeks). TRD affects an estimated 30 percent of all patients diagnosed with major depression and represents one of the most significant challenges in modern psychiatry. It is also the clinical population for which ketamine therapy has shown the strongest evidence of benefit.
Diagnostic Criteria
There is no universally standardized definition of TRD, but the most commonly used clinical threshold requires failure of at least two adequate antidepressant trials from different pharmacological classes. An "adequate trial" is generally defined as:
- A therapeutic dose (not a subtherapeutic starting dose)
- Maintained for at least six weeks at the target dose
- Reasonable medication adherence confirmed by the patient
Some staging systems classify TRD by severity. The Thase-Rush staging model, for example, assigns higher stages to patients who have failed increasing numbers of treatment classes — from a single SSRI failure (Stage I) through failure of multiple classes including MAOIs and electroconvulsive therapy (Stage V). The Massachusetts General Hospital staging method uses a quantitative scoring system that accounts for the number, duration, and optimization of failed trials.
In clinical practice, many patients labeled as treatment-resistant have actually experienced pseudo-resistance — apparent treatment failure caused by inadequate dosing, insufficient trial duration, misdiagnosis (such as unrecognized bipolar disorder), poor medication adherence, or untreated comorbid conditions like thyroid dysfunction or substance use disorders.
Scope of the Problem
The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial, the largest and most rigorous study of depression treatment outcomes, found that only about one-third of patients achieved remission with their first antidepressant. With each subsequent medication trial, remission rates declined further — from 37 percent with the first drug to roughly 13 percent by the fourth trial. By the time patients had failed two or more treatments, their likelihood of responding to yet another conventional antidepressant was substantially diminished.
TRD carries an enormous burden. Patients with treatment-resistant depression experience higher rates of hospitalization, suicide attempts, disability, and lost productivity compared to those whose depression responds to standard treatment. The economic costs are correspondingly high, with TRD patients incurring healthcare expenditures two to three times greater than those of patients with treatment-responsive depression.
Why Ketamine Matters for TRD
Ketamine represents a fundamentally different approach to treating depression. Unlike SSRIs, SNRIs, and other monoamine-based antidepressants, ketamine works primarily through the glutamatergic system by blocking NMDA receptors. This distinct mechanism means that ketamine can be effective even in patients whose depression has not responded to serotonin- or norepinephrine-based treatments.
Clinical trials have consistently demonstrated that a single intravenous infusion of ketamine at a sub-anesthetic dose (typically 0.5 mg/kg over 40 minutes) produces significant antidepressant effects in approximately 50 to 70 percent of TRD patients, with response often apparent within hours. This rapid onset stands in stark contrast to the weeks or months of trial-and-error required by conventional approaches.
The FDA's 2019 approval of esketamine (the S-enantiomer of ketamine) nasal spray was specifically limited to treatment-resistant depression, formally recognizing TRD as ketamine's primary therapeutic indication. Racemic ketamine administered intravenously or as oral formulations through compounding pharmacies is also widely used off-label for TRD.
Ongoing Challenges
Despite ketamine's efficacy, TRD remains a complex clinical problem. The duration of ketamine's antidepressant effects varies considerably between patients, with many requiring repeated treatments to maintain response. Identifying which TRD patients are most likely to respond to ketamine — and developing strategies to extend the duration of benefit — are active areas of research. For more on this topic, see our 2025 research roundup.
References
- STAR*D Trial Results — Rush et al. (2006), American Journal of Psychiatry. Definitive evidence on antidepressant remission rates.
- Treatment-Resistant Depression: Definition and Assessment — Berlim and Turecki (2007), Journal of Clinical Psychiatry. Review of TRD staging systems.
- A Consensus Statement on Treatment-Resistant Depression — McIntyre et al. (2014), Journal of Clinical Psychiatry. Expert consensus on TRD criteria.
- NIMH Depression Overview — National Institute of Mental Health resource on depression and treatment options.
Share